Welcome to our dedicated page for Edwards Lifesciences SEC filings (Ticker: EW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TAVR adoption rates, clinical-trial milestones, and FDA approvals fill Edwards Lifesciences’ disclosures with dense medical jargon. If you’ve sifted through a 300-page report just to isolate heart-valve revenue or R&D costs, you know the challenge. Stock Titan turns that complexity into clarity: our AI reads every page the moment it reaches EDGAR and surfaces the metrics cardio-device investors actually track.
Need the latest numbers? The Edwards Lifesciences quarterly earnings report 10-Q filing appears here with instant commentary on transcatheter valve growth. Wondering whether insiders are signalling confidence? Track Edwards Lifesciences insider trading Form 4 transactions and receive Edwards Lifesciences Form 4 insider transactions real-time alerts. Our coverage also delivers every Edwards Lifesciences 8-K material events explained, so product recalls or trial updates never catch you off-guard—making Edwards Lifesciences SEC filings explained simply a reality.
The insight goes deeper. Open the Edwards Lifesciences annual report 10-K simplified to see margin shifts across Surgical Structural Heart, or review the Edwards Lifesciences proxy statement executive compensation to benchmark pay against peer med-tech firms. Jump from Edwards Lifesciences executive stock transactions Form 4 directly to our Edwards Lifesciences earnings report filing analysis with one click. Whether you manage portfolios or run cardiovascular research, understanding Edwards Lifesciences SEC documents with AI means minutes, not hours, of due diligence.
- AI-powered summaries in plain English
- Real-time alerts the second filings hit EDGAR
- Full archive of every form, from 10-K to S-8
Edwards Lifesciences (EW) Form 4 filing: Corporate Vice-President Annette Bruls reported one transaction on 07/11/2025. A total of 109 shares of common stock were withheld for tax purposes (Transaction Code F) at a price of $78.80 per share. Following the withholding, Bruls directly owns 14,171 EW shares. No derivative security activity or additional transactions were disclosed. The filing reflects routine administrative share withholding rather than an open-market sale.
Edwards Lifesciences (EW) – Form 4 insider filing
Corporate Vice President Daniel J. Lippis reported a single transaction dated 07 July 2025. Using transaction code F (shares withheld to cover taxes), 333 shares of common stock were disposed of at an average price of $76.79 per share. Following the tax-related withholding, Lippis’ direct beneficial ownership stands at 26,115.9103 shares.
No derivative securities were reported and no other acquisitions or dispositions were disclosed. The filing notes the routine quarterly purchase activity under the company’s Employee Stock Purchase Plan, but those acquisitions are not itemised in the tables. Given the small size of the tax-related disposition (≈1.3 % of the insider’s holdings) and the absence of open-market sales, the transaction is unlikely to have a material impact on the company’s share supply or insider-ownership sentiment.
FAQ
What is the current stock price of Edwards Lifesciences (EW)?
What is the market cap of Edwards Lifesciences (EW)?
What is Edwards Lifesciences Corp known for?
Which core product categories does the company offer?
How does Edwards Lifesciences generate revenue?
What differentiates Edwards Lifesciences from its competitors?
In which markets does the company operate?
How does the company ensure product reliability and quality?
What role do clinical partnerships play in the company’s success?
How is Edwards Lifesciences positioned in the global healthcare industry?
